357 related articles for article (PubMed ID: 36799062)
1. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
[TBL] [Abstract][Full Text] [Related]
2. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
Lee H; Lim TS; Kim SU; Kim HC
Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.
Eren F; Kaya E; Yilmaz Y
Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):98-103. PubMed ID: 32976186
[TBL] [Abstract][Full Text] [Related]
5. Metabolic puzzle: Exploring liver fibrosis differences in Asian metabolic-associated fatty liver disease subtypes.
Shaikh SS; Qazi-Arisar FA; Nafay S; Zaheer S; Shaikh H; Azam Z
World J Hepatol; 2024 Jan; 16(1):54-64. PubMed ID: 38313248
[TBL] [Abstract][Full Text] [Related]
6. Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study.
Zhang Y; Xia Z; Cai X; Su X; Jin A; Mei L; Jing J; Wang S; Meng X; Li S; Wang M; Wei T; Wang Y; He Y; Pan Y
Cardiovasc Diabetol; 2023 Dec; 22(1):342. PubMed ID: 38093371
[TBL] [Abstract][Full Text] [Related]
7. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease.
Fan H; Li L; Liu Z; Zhang P; Wu S; Han X; Chen X; Suo C; Cao L; Zhang T
BMC Gastroenterol; 2023 Jan; 23(1):3. PubMed ID: 36604612
[TBL] [Abstract][Full Text] [Related]
8. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
Cheng YM; Wang CC; Kao JH
Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
[TBL] [Abstract][Full Text] [Related]
9. The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study.
Xing M; Ni Y; Zhang Y; Zhao X; Yu X
Front Nutr; 2023; 10():1246157. PubMed ID: 38024359
[TBL] [Abstract][Full Text] [Related]
10. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
11. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
[TBL] [Abstract][Full Text] [Related]
14. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
[TBL] [Abstract][Full Text] [Related]
15. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
[TBL] [Abstract][Full Text] [Related]
16. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease.
Sohn W; Kwon HJ; Chang Y; Ryu S; Cho YK
Clin Gastroenterol Hepatol; 2022 May; 20(5):e1135-e1148. PubMed ID: 34224877
[TBL] [Abstract][Full Text] [Related]
17. Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center.
Guan C; Fu S; Zhen D; Yang K; An J; Wang Y; Ma C; Jiang N; Zhao N; Liu J; Yang F; Tang X
J Diabetes Res; 2022; 2022():8429847. PubMed ID: 35127953
[TBL] [Abstract][Full Text] [Related]
18. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study.
Park MK; Hur MH; Moon HS; Shin H; Chung SW; Won S; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Liver Int; 2024 Mar; 44(3):799-810. PubMed ID: 38230848
[TBL] [Abstract][Full Text] [Related]
19. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
20. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study.
Zhao Q; Yin Y; Deng Y
Nutr Diabetes; 2023 Nov; 13(1):21. PubMed ID: 37968264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
